Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of TQB2930 plus TQB2102 in HER2-expressing advanced solid tumors
CTR20260932Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2930, TQB2102 in Nonhematologic neoplasms, sponsored by Nanjing Shunxin Pharmaceutical. Started May 2026; status: active.
02
Drugs
TQB2930TQB2102
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20260932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260932.